Management of Psoriasis Vulgaris with Methotrexate 0.25% in a Hydrophilic Gel: A Placebo-Controlled, Double-Blind Study

2001 ◽  
Vol 5 (4) ◽  
pp. 299-302 ◽  
Author(s):  
Tanweer A. Syed ◽  
Suhail M. Hadi ◽  
Zulfiqar A. Qureshi ◽  
Christine G. Nordstrom ◽  
Shahida M. Ali
Keyword(s):  
Psoriasis Vulgaris ◽  
Topical Therapy ◽  
Severity Index ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Plaque Type ◽  
Normal Limits ◽  
Pasi Score ◽  
Hydrophilic Gel

Background: Methotrexate has been used as one of the first and systemic therapies for psoriasis. In general, 70% of patients with psoriasis prefer topical therapy as the treatment of choice. Objective: The purpose of this placebo-controlled double-blind study was to evaluate the clinical efficacy and tolerability of methotrexate 0.25% incorporated in a hydrophilic gel (hydroxyethylcellulose 1%) to treat patients afflicted with psoriasis vulgaris. Methods: Sixty patients (37M/23F) ranging between 18 and 70 years of age, with slight to moderate chronic plaque-type psoriasis and PASI (Psoriasis Area and Severity Index) scores between 5.3 and 17.5 joined the study. The mean duration of the disease at entry was 9.6 years (range 1–24 years). The diagnosis of psoriasis was established by clinical and histopathologic methods. Patients were sequentially randomized into two parallel groups. Each patient was allocated a precoded 100-g tube (active or placebo) with instructions on how to self-administer the trial medication topically (without occlusion) to their lesions two times daily for 5 consecutive days per week. The study lasted for 12 weeks with 4 weeks of active treatment. Patients were examined on a weekly basis and those showing total clearing or remission of lesions were considered effectively treated. Results: By the end of the treatment, breaking the code disclosed that methotrexate 0.25% gel had significantly treated more patients than placebo (83.3% vs. 6.7%; p < 0.0001), reduced the PASI score to a mean of 2.2, and cleared more plaques (82.2% vs. 4.3%; p < 0.0001). Laboratory evaluations, including CBC with differential and platelet count, renal function, liver chemistry [SGOT (aspartate transaminase) and SGPT (alanine transaminase)], and serum creatinine, were within the normal limits. The treatment was well-tolerated by all the patients, with no adverse drug-related symptoms and no dropouts. The study was followed up for 12 months from the first day of the treatment; two cured patients had relapsed after 8 months. Conclusion: The findings of this study demonstrate that methotrexate 0.25% in a hydrophilic gel is well tolerated and significantly more effective than placebo as a patient-applied topical medication to treat psoriasis vulgaris.

Management of Psoriasis Vulgaris with Methotrexate 0.25% In a Hydrophilic Gel: A Placebo-Controlled, Double-Blind Study

2001 ◽  
Vol 5 (4) ◽  
pp. 299-302 ◽  
Author(s):  
Tanweer A. Syed ◽  
Suhail M. Hadi ◽  
Zulfiqar A. Qureshi ◽  
Christine G. Nordstrom ◽  
Shahida M. Ali
Keyword(s):  
Psoriasis Vulgaris ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Hydrophilic Gel

scholarly journals PSORIASIS VULGARIS PADA BAYI

2014 ◽  
Vol 6 (1) ◽  
Author(s):  
Shienty Gaspersz ◽  
Herry E. J. Pandaleke
Keyword(s):  
Vitamin D3 ◽  
Psoriasis Vulgaris ◽  
Age Of Onset ◽  
Severity Index ◽  
Psoriasis Area Severity Index ◽  
Normal Limits ◽  
Severity Index Score ◽  
Pasi Score ◽  
Erythematous Plaques ◽  
Topical Emollient

Abstract: Psoriasis may begin at any age but most often after puberty and only about 2% occurs in less than 2 years of age. The age of onset plays an important role because early onset psoriasis accompanied by a psoriasis family history is more severe and has a tendency to relapse. The treatment for mild psoriasis is topical and phototherapy. The first-line treatment is topical emollient, glucocorticoids, and vitamin D3 analog. We reported a case of a 3-month-old female infant presenting erythematous plaques with scales on scalp, face, neck, chest, tummy, armpit, back, buttock, and groin accompanied with irritability that had occured for a week. The Psoriasis Area Severity Index score (PASI) was 7% and laboratory examinations were within normal limits. Treatment with topical desonide 0.05% for 1 week did not result in any improvement. The treatment was changed to topical mometason furoat 0.1%. After 7 weeks of therapy, the plaques became flattened and less pigmented, and the PASI score decreased to 0.9%.Keywords: psoriasis vulgaris, infant  Abstrak: Usia awitan psoriasis bervariasi dari bayi hingga usia lanjut, namun sebagian besar timbul setelah pubertas dan hanya sekitar 2% terjadi pada usia kurang dari 2 tahun. Usia awitan perlu diketahui karena semakin dini usia awitan disertai adanya riwayat keluarga dengan psoriasis, perjalanan penyakit akan makin berat dan makin sering kambuh. Pilihan pengobatan pada psoriasis ringan (< 10%) ialah pengobatan topikal dan fototerapi. Pengobatan topikal lini pertama ialah emolien, glukokortikoid, dan analog vitamin D3. Kami melaporkan seorang bayi perempuan berusia 3 bulan yang datang dengan plak eritematosa, berbatas tegas, ukuran bervariasi, dengan skuama pada kepala, wajah, leher, dada, perut, ketiak, punggung, bokong, dan selangkangan, disertai rewel sejak 1 minggu lalu. Perhitungan Psoriasis Area Severity Index (PASI) 7%. Pemeriksan laboratorium masih dalam batas normal. Pasien diterapi dengan krim desonide 0,05%, namun setelah 1 minggu tidak terdapat perbaikan yang memuaskan, sehingga diganti dengan krim mometason furoat 0,1%. Setelah 7 minggu menggunakan mometason furoat, bercak merah yang awalnya meninggi menjadi hipopigmentasi dan mendatar serta perhitungan PASI menjadi 0,9%.Kata kunci: psoriasis vulgaris, bayi

scholarly journals Comparative Efficacy of Topical Calcipotriol (0.005%) Versus Topical Corticosteroid (Betamethasone 0.1%) in Treating Plaque Type Psoriasis

2015 ◽  
Vol 26 (2) ◽  
pp. 88-94
Author(s):  
Gulam Kazem Ali Ahmed ◽  
Lubna Khandker ◽  
Moriom Nessa ◽  
Mohd Nurul Alam ◽  
Anjana Chakraborty ◽  
...  
Keyword(s):  
Topical Corticosteroid ◽  
Base Line ◽  
Double Blind Study ◽  
Double Blind ◽  
Plaque Type ◽  
Pasi Score ◽  
Group A ◽  
The Mean ◽  
Group B ◽  
Medical University

A clinical trial was carried out to compare the efficacy of topical calcipotriol (0.005%) and topical corticosteroid (betamethasone 0.1%) in the treatment of plaque type psoriasis. The study was conducted from January 2012 to August 2012 and patients of plaque type psoriasis attending outpatient department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University, Dhaka were the study population. Patients were divided into two groups, group A was treated with topical calcipotriol (0.005%) ointment and group B with topical corticosteroid (betamethasone 0.1%) ointment. The mean baseline PASI score was 6.7 ±4.5 and after 8 weeks, the mean PASI score was 2.0 ±1.4 for group A and mean baseline PASI score was 5.5 ±4.2 and after 8 weeks, the mean PASI score was 2.5 ±1.4 for group B. There was statistically significant reduction in PASI score from base line after 8 weeks of treatment in both treatment groups (p < 0.001). After 8th week of treatment moderate response was 11(73.3%) in group A and 9(60%) in group B. Very good response was 4 (26.7%) in group B and 2 (13.3%) in group A and minimal response of treatment occurs equally 2 (13.3%) in group A and group B. In the light of the findings of the study we conclude that each of the treatment of calcipotriol(0.005%) and betamethasone (0.1%) is individually effective. Further multicenter, randomized, double-blind study should be conducted with large sample size.Medicine Today 2014 Vol.26(2): 88-94

Management of intravaginal warts in women with 5-fluorouracil (1%) in vaginal hydrophilic gel: a placebo-controlled double-blind study

2000 ◽  
Vol 11 (6) ◽  
pp. 371-374 ◽  
Author(s):  
Tanweer A Syed Md ◽  
A Qureshi ◽  
Seyed Ali Ahmad ◽  
Shahida M Ali
Keyword(s):  
Blot Hybridization ◽  
Clinical Signs ◽  
Southern Blot Hybridization ◽  
Clinical Results ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Hpv Dna ◽  
Hydrophilic Gel ◽  
To Receive

The purpose of this placebo-controlled, double-blind study was to determine the safety, tolerability and clinical efficacy of 5-fluorouracil (1%) in a vaginal hydrophilic gel (hydroxyethylcellulose, 1%) to cure intravaginal papillomas in women. Pre-selected, 60 women ranging between 18 and 50 years of age (mean 24.6), having 312 vaginal condylomas (mean 5.2) joined the study. The diagnosis of human papillomavirus (HPV) was established with clinical, histopathological and polymerase chain reaction (PCR) techniques. Subjects were randomized into 2 parallel groups. Each patient was allocated a pre-coded tube 15 g (active or placebo) with graduated vaginal applicators (disposable), and instructions how to insert 4 g of the trial medication deep into the vagina once at bedtime on every other day (1, 3 and 5) per week, to visit the clinic on day 7 for clinical evaluations and to receive the same pre-coded replacement to continue the regimen for another week. A maximum 12 applications were to be used in 4 weeks. Cure was defined as absence of clinical signs of infection, re-confirmed by PCR and Southern blot hybridization negative HPV DNA. By the end of the treatment 48.4% patients and 51.9% lesions were cured. Breaking the code revealed that 5-fluorouracil (1%) gel had cured 83.3% patients and 87% intravaginal warts. Placebo resolved 13.3% patients and 14% condylomas; (active gel versus placebo; P < 0.001). Twelve patients (20%) mostly in the active gel experienced mild erythema, erosion and oedema, with no drop-outs. Among cured patients 3 had a relapse after 16 months. In conclusion, the clinical results of the study demonstrate that 5-fluorouracil (1%) in a vaginal hydrophilic gel is safe, tolerable and significantly more effective than placebo to cure intravaginal warts in women.

Betamethasone-17,21-Dipropionate with Salicylic Acid, a Double-Blind Comparative Evaluation with Flumethasone-21-Pivalate with Salicylic Acid in the Treatment of Psoriasis

1975 ◽  
Vol 3 (6) ◽  
pp. 368-370 ◽  
Author(s):  
Gunnel Eriksson
Keyword(s):  
Salicylic Acid ◽  
Comparative Evaluation ◽  
Psoriasis Vulgaris ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind

A double-blind study has shown that 0.05% betamethasone-17,21- dipropionate ointment with 3% salicylic acid is more effective than 0.02% flumethasone-21- pivalate ointment with 3% salicylic acid in patients with psoriasis vulgaris treated for three weeks.

Sign in / Sign up

Export Citation Format

Share Document